Candel Therapeutics Secures $100M Royalty Deal for Prostate Cancer Therapy Launch
Event summary
- Candel Therapeutics secured a $100M royalty funding agreement with RTW Investments, contingent on FDA approval of aglatimagene besadenovec (CAN-2409) for localized prostate cancer.
- Funds will support the potential U.S. commercial launch of CAN-2409, with royalties based on annual net sales.
- Candel plans to submit a Biologics License Application (BLA) for CAN-2409 in Q4 2026.
- CAN-2409 received Fast Track and Regenerative Medicine Advanced Therapy Designations from the FDA.
The big picture
This deal underscores investor confidence in Candel’s pipeline, particularly in the prostate cancer space, where CAN-2409 could disrupt treatment paradigms. The non-dilutive financing strengthens Candel’s balance sheet ahead of a potential 2026 launch, positioning it as a key player in oncology immunotherapies. The strategic partnership with RTW highlights the growing trend of royalty-based funding in biotech, reducing dilution risks for companies nearing commercialization.
What we're watching
- Regulatory Approval
- Whether the FDA will approve CAN-2409 for localized prostate cancer by the anticipated timeline, given its Fast Track designation.
- Commercial Execution
- How Candel will deploy the $100M in funding to build a world-class commercial program for CAN-2409.
- Market Adoption
- The pace at which CAN-2409 could capture market share in a prostate cancer segment that has seen minimal innovation in two decades.
Related topics